Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial
The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.
New physician Medicare payments for the Agent drug-coated balloon set for 2027
Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027.
SCAI: To improve cardiogenic shock outcomes, reduce lactate levels
SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data.
Siemens Healthineers and Boston Scientific partner on next-generation intracardiac echo for LAAO
The agreement also will make Boston Scientific the exclusive distributor for the new ICE catheter optimized for left atrial appendage occlusion workflows.
Toddler dies after allegedly being given 10 times too much potassium due to decimal error
A lawsuit contends that De’Markus Page, 2 years old, died because no one at University of Florida Health’s Shands Teaching Hospital spotted the errors, which should have been labeled as a “red flag” by EHR systems.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Boston Scientific said it initiated the AGENT DCB STANCE trial to assess the safety and effectiveness of the Agent Drug-Coated Balloon (DCB) compared to the standard of care using either percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and/or balloon angioplasty. The trial will enroll more than 1,600 patients and is expected to a primary completion date in 2028.

New physician Medicare payments for the Agent drug-coated balloon set for 2027

Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027.

Society of Cardiovascular Angiography and Interventions (SCAI) President Srihari S. Naidu, MD, professor of medicine at New York Medical College, explains the SCAI initiative to improve outcomes in cardiogenic shock by monitoring and lowering patient lactate levels.

SCAI: To improve cardiogenic shock outcomes, reduce lactate levels

SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data.

Siemens Healthineers and Boston Scientific partner on next-generation intracardiac echo for LAAO

The agreement also will make Boston Scientific the exclusive distributor for the new ICE catheter optimized for left atrial appendage occlusion workflows.

Toddler dies after allegedly being given 10 times too much potassium due to decimal error

A lawsuit contends that De’Markus Page, 2 years old, died because no one at University of Florida Health’s Shands Teaching Hospital spotted the errors, which should have been labeled as a “red flag” by EHR systems.

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.

Illustration showing how procizumab captures circulating dipeptidyl peptidase 3 (cDPP3) to block this key molecular driver of shock. Illustrations courtesy of 4TEEN4

$64M raised for new cardiogenic shock drug—research already underway

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.